Carfilzomib Dosage

Generic name: carfilzomib
Brand name: Kyprolis
Dosage form: intravenous (infusion) injection
Drug class: Proteasome inhibitors

Medically reviewed by  A Ras MD.

 

Recommended Adult Dosing

Dosage forms:  INJ

Special Note

[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, concomitant meds to mitigate toxicity, and dosing incl. toxicity-related dose adjustments; for pts w/ BSA >2.2 m^2, cap BSA at 2.2 m^2 for dose calculations

Multiple myeloma, relapsed or refractory

[monotherapy, 27 mg/m^2 dose]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 27 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 27 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle for cycles 2-12, then 27 mg/m^2/dose IV x1 on days 1, 2, 15, 16 of 28-day cycle starting cycle 13 until dz progression; Info: use w/ VTE prophylaxis
[monotherapy, 56 mg/m^2 dose]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 56 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 56 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle for cycles 2-12, then 56 mg/m^2/dose IV x1 on days 1, 2, 15, 16 of 28-day cycle starting cycle 13 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ dexamethasone, once weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on day 1, then 70 mg/m^2/dose IV x1 on days 8 and 15 of 28-day cycle for cycle 1, then 70 mg/m^2/dose IV x1 on days 1, 8, 15 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ dexamethasone, twice weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 56 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 56 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ lenalidomide and dexamethasone]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 27 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 27 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle for cycles 2-12, then 27 mg/m^2/dose IV x1 on days 1, 2, 15, 16 of 28-day cycle for cycles 13-18; Info: use w/ VTE prophylaxis
[combo w/ daratumumab and dexamethasone, once weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on day 1, then 70 mg/m^2/dose IV x1 on days 8 and 15 of 28-day cycle for cycle 1, then 70 mg/m^2/dose IV x1 on days 1, 8, 15 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ daratumumab and dexamethasone, twice weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 56 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 56 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ daratumumab/hyaluronidase and dexamethasone, once weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on day 1, then 70 mg/m^2/dose IV x1 on days 8 and 15 of 28-day cycle for cycle 1, then 70 mg/m^2/dose IV x1 on days 1, 8, 15 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ daratumumab/hyaluronidase and dexamethasone, twice weekly regimen]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 56 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 56 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis
[combo w/ isatuximab and dexamethasone]
Dose: 20 mg/m^2/dose IV x1 on days 1 and 2, then 56 mg/m^2/dose IV x1 on days 8, 9, 15, 16 of 28-day cycle for cycle 1, then 56 mg/m^2/dose IV x1 on days 1, 2, 8, 9, 15, 16 of 28-day cycle starting cycle 2 until dz progression; Info: use w/ VTE prophylaxis

Renal dosing

CrCl >15: no adjustment; CrCl <15: not defined
HD: no adjustment, on dialysis days admin. after dialysis; no supplement; PD: not defined

Hepatic dosing

[adjust dose amount]
bilirubin 1-3x ULN or AST >ULN: decr. dose 25%; bilirubin >3x ULN and any AST: not defined

 

SRC: NLM .